Substance / Medication

Posaconazole

Overview

Active Ingredient
posaconazole
RxNorm CUI
282446
Labeler: GLENMARK PHARMACEUTICALS INC., USAUpdated: 2026-02-11T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

7 trials linked to this intervention

7
Total Trials
0
Recruiting
4
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Posaconazole effectiveness in rare invasive fungal infections: A systematic literature review.
Bernauer Mark, Waskin Hetty, Cossrow Nicole et al. · Int J Antimicrob Agents · 2025
PMID: 40023451Meta-Analysis
Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.
Weerdenburg Heather, Walker Hannah, Haeusler Gabrielle M et al. · J Antimicrob Chemother · 2025
PMID: 40037294Meta-AnalysisFull text (PMC)
Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.
Qu Ruochen, Liu Yan, Zhao Yan et al. · Front Pharmacol · 2024
PMID: 39749194Meta-AnalysisFull text (PMC)
Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.
Boutin Catherine-Audrey, Durocher Florence, Beauchemin Stéphanie et al. · Clin Infect Dis · 2024
PMID: 38752732Meta-AnalysisFull text (PMC)
Dose adjustment of immunosuppressants during co-administration of posaconazole: a systematic review.
Fu Chengcheng, Chen Jia, Xu Yang et al. · Clin Invest Med · 2018
PMID: 29603686Meta-Analysis
Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers.
Moton A, Krishna G, Wang Z · J Clin Pharm Ther · 2009
PMID: 19646076Meta-Analysis
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment.
Olkkola Aleksi M, Tapaninen Tuija, Tornio Aleksi et al. · Br J Clin Pharmacol · 2024
PMID: 37872104RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Posaconazole (substance)
SNOMED CT
421747003
UMLS CUI
C0936148
RxNorm CUI
282446
Labeler
GLENMARK PHARMACEUTICALS INC., USA

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
7
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.